A new technique may enable more accurate
brain tumor diagnoses through a combination
of advanced optical imaging and AI
NYU and UM researchers bring optical imaging and AI to brain tumor diagnoses
January 08, 2020
by John R. Fischer
, Senior Reporter
Researchers at NYU Grossman School of Medicine and the University of Michigan are proposing a new approach that may lead to more accurate brain tumor diagnoses by combining advanced optical imaging and artificial intelligence.
Using a NIO Imaging System, the scientists applied an imaging technique known as stimulated Raman histology (SRH) and performed AI-based real-time intraoperative diagnoses of brain tumors. They then compared the accuracy to that of manual interpretations of conventional histological images performed by pathologists, finding both to be similar to one another.
"The brain is made up primarily of gray matter (primarily neurons and supporting cells) and white matter (primarily axons — the wire-like processes that neurons send out to other neurons and muscles in body)," Dr. Daniel Orringer, associate professor of neurosurgery at NYU Langone Health, told HCB News. "Axons, in particular, are very hard to see with conventional histology. On the other hand, SRH reveals axons particularly well because it is sensitive to the lipids that line them. Axons become really important in differentiating tumors that arise from the brain (gliomas, glioblastoma) and those that have spread to the brain (metastatic cancer) or compress the brain (meningioma)."
In addition to allowing surgeons to see things that would otherwise be invisible, the technology allows surgeons to improve speed and accuracy in the OR and reduce the risk of misdiagnosis.
Stimulated Raman histology collects and utilizes scattered laser light to reveal tumor infiltration in human tissue, and illuminates essential features not typically observed in standard histological images. While conventional histology relies on processed tissue and stains that wash away lipids, SRH uses lipids specifically to generate contrast in images.
The researchers applied AI to process and analyze the microscopic images, producing results and allowing surgeons to view a predicted brain tumor diagnosis in under two and a half minutes. Following the resection, the same technology was used to accurately detect and remove the otherwise undetectable tumor.
Researchers developed the AI tool by training a deep convolution neural network (CNN) with more than 2.5 million samples from 415 patients to classify tissue into 13 histological categories that represent the most common brain tumors, including malignant gliomas, lymphoma, metastatic tumors, and meningioma.
To test the accuracy of the CNN, researchers enrolled 278 patients in a prospective clinical trial to undergo brain tumor resection or epilepsy surgery at three university medical centers. Brain tumor specimens were biopsied from patients, split intraoperatively into sister specimens, and randomly assigned to a control arm or an experimental arm.
Those in the control arm, which represented the current standard practice, underwent specimen processing, slide preparation by technicians, and interpretation by pathologists, a process which takes 20-30 minutes. The experimental arm was performed intraoperatively, with the CNN conducting the entire process from image acquisition and processing to diagnostic prediction. The pathologist-based interpretation was 93.9 percent, compared to the AI-based diagnosis, which scored 94.6 percent accurate.
The unique nature of diagnostic errors in the experimental group compared to those in the control group suggests that a pathologist using the approach could score close to 100 percent accuracy. The system’s strong diagnostic ability could also benefit centers that lack available expert neuropathologists.
"SRH will revolutionize the field of neuropathology by improving decision-making during surgery and providing expert-level assessment in the hospitals where trained neuropathologists are not available," said co-author Dr. Matija Snuderl, an NYU Langone neuropathologist, and molecular pathologist, and associate professor in the department of pathology at NYU Grossman School of Medicine, in a statement.
The findings were published in Nature Medicine.